Clinical Trial

Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Completed Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a pilot, single-center, single-arm study where 20 patients with metastatic or unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks \[Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG\]).
Protocol Amendment History 4 changes
critical Trial completed 2026-07-30
notable Enrollment reduced: 20 -> 10 participants 2026-07-30
notable Primary completion moved earlier: 2026-09 -> 2026-06-05 2026-07-30
minor Completion moved earlier: 2026-12 -> 2026-06-05 2026-07-30
Trial Details
NCT Number NCT05188118
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions Renal Cell Carcinoma
Enrollment 10 participants
Start Date 2023-02-15
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-29